A Single AFP Number Tells Half the Story
Alpha-fetoprotein (AFP) is a standard biomarker in cancer medicine. Patients at high risk for hepatocellular carcinoma (HCC) - those with cirrhosis, hepatitis B or C, or advanced liver scarring - get an AFP blood test every six months along with a liver ultrasound. But a single AFP number on its own doesn't tell the full story.
What matters is the pattern. A slow, steady climb in AFP over three or four tests may show early tumor activity before a spot shows up on imaging. A sharp spike in one test may come from a benign hepatitis flare. A steady climb over several tests is usually a real problem. The speed and direction of change in AFP numbers over time is called AFP velocity.
Tracking that velocity by hand, across dozens of high-risk patients with months between visits, is a problem most clinics face.
The Clinical Evidence for Longitudinal AFP Tracking
The current AASLD Practice Guidance on HCC includes AFP as part of surveillance every six months for high-risk patients. The guidance notes that AFP and ultrasound together may find early tumors better than ultrasound alone. AFP is not a tool that works alone. But tracking AFP over time adds real value to what imaging shows.
An automated system that tracks AFP numbers over time in a study of patients with hepatitis C and advanced scarring found better detection of HCC. The system flagged rapid rises in AFP before numbers crossed the usual alert level.
An analysis of how AFP changes over time showed that tracking changes found high-risk patients better than single AFP tests. The system's accuracy was much higher than looking at one number.
Using several blood markers together gives better results. The GALAD score uses AFP, AFP-L3, DCP, age, and sex to find HCC cases at any stage (75.8% sensitivity) and early-stage cases (57.8% sensitivity) with high accuracy (93.5%) in a recent study. Even without the full GALAD score, tracking AFP changes over time is a key signal that should be collected regularly.
Where the Workflow Breaks Down
Every cancer clinic with patients who have cirrhosis or hepatitis B faces the same problem: when a patient comes back after six months, their old AFP numbers might be in a different part of the medical record, a scanned PDF, or their hepatologist's system.
A study across multiple centers found that patients missed appointments and tests were missed mostly because of system problems, not because patients didn't comply. Patients in surveillance programs missed their six-month AFP and imaging appointments without any alert going to their doctors.
An automated system that reminded patients to come in worked well with a diverse group of patients with cirrhosis. Patients with viral liver disease needed regular reminders to stay in the program. When you rely on people to remember, appointments get missed without anyone noticing.
For doctors, this means opening a patient chart before a visit and spending the first ten minutes digging through notes and different lab systems to find the AFP trend. Finding what should take thirty seconds takes ten minutes. That time comes out of the patient visit.
How Lab Systems Can Track AFP Velocity
A lab system can collect AFP results from different lab interfaces, PDF reports, and connected systems and match each result to the right visit date. When a new AFP value comes in, it appears automatically on the patient's AFP trend line, right at the top of the chart without needing to open a separate tab or PDF.
The AFP velocity calculation happens automatically. When a patient's AFP rises over several tests at a fast enough rate, a prompt shows up in the patient chart. The doctor can note the flag, add it to the visit notes, or request an imaging scan from the same screen. The calculation and alert are automatic.
More on this approach can be found in how lab data extraction changes clinic work. The key idea is to use a series of lab values to spot problems early, not just keep a record of past results.
The same approach works for PSA velocity in prostate cancer, as described in PSA Velocity Tracking in Prostate Cancer Active Surveillance. In both cases, tracking change over time matters more than any single number.
Setting Up AFP Surveillance Schedules
Every HCC program has different rules depending on the cause of the liver disease, how damaged the liver is, and what the clinic does. A clinic team can set up recurring AFP orders every six months that attach to a patient's surveillance plan. When an AFP test is due, the order shows up in the doctor's work list. If a result comes in late or not at all, the system alerts the team instead of moving ahead with the schedule.
A clinic can assign one main doctor and a backup to track each patient's AFP tests. Results go to the right doctor at the right time. Keeping track of what was ordered, what came back, and what the trend looks like helps catch missed appointments, just as with TSH suppression monitoring for thyroid cancer.
The Difference a Trendline Makes
Take a patient with cirrhosis from hepatitis C who responded to antiviral drugs. Their AFP starts at 6 ng/mL when surveillance begins. Over 18 months, it rises to 9, then 12, then 18 ng/mL. Each number is below the usual 20 ng/mL alert level. Each one looks normal on its own. But on a chart, the pattern is not.
A doctor looking only at single numbers would see no numbers over 20, so no imaging scan gets ordered. Tracking the trend shows a threefold rise over 18 months. After three rises in a row, an alert goes out. The imaging scan gets ordered before 20 ng/mL is reached.
A study of regular AFP testing found that patients who got consistent AFP tests every six months were more likely to get treatment that cured their cancer than those with irregular testing. Spotting the trend instead of looking at one number is what makes catching cancer earlier possible.
Demos take 30 minutes. A demonstration walks through how to set up AFP velocity tracking and manage follow-up appointments. Book a demo to learn how AFP tracking fits into HCC surveillance.